Melanoma Matters Pod

Melanoma Matters

Health EN ↓ 95 episodes

From the UK to the USA - Melanoma Matters is on a mission! Hosts James Larkin and Sapna Patel are spreading the word on melanoma, one podcast at a time. Tune in for a critical review of the literature and a discussion of how we incorporate the data into our practices...across the pond(s). #MelanomaMatters video podcast

Be sure to visit the podcast's website and support the creator: www.melanomamatters.com

Author

Melanoma Matters Pod

Category

Health

Podcast website

www.melanomamatters.com

Latest episode

Oct 16, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

Preview of a PREVIEW 16.10.2026

ADCs are coming in melanoma and James is stunned into silence for 45s

Ep 89: PREVIEW ESMO Annual Meeting: 2026 Madrid 16.10.2026

James and Sapna discuss all the meanings of the word "pike" and preview the presentations they are looking forward to at the 2026 ESMO Annual Congress from the Melanoma and Skin Tumours track. Sapna wants to see all of you at the poster session on Saturday 24 October 2026 from 1200 to 1245h Nos vemos pronto en Madrid!

Ep 88: Negative Adjuvant Doublet Studies (CM915, KV010, RELA098) 01.09.2026

Melanoma Matters: Why Adjuvant Doublet Immunotherapy Fell Short Hobbies - James wishes he was surfing more This episode breaks down three negative adjuvant melanoma trials testing combination immunotherapy against anti PD 1 monotherapy. The discussion focuses on why toxicity rises without clear efficacy gains, and what these results mean for adjuvant and neoadjuvant strategy going forward. James L...

Ep 86: Teaser Tudriqev (RP1) FDA Approval 25.08.2026

James asks the big question

Ep 87: INTerpath-001 Press Release - August 2026 25.08.2026

In this episode, Sapna and James discuss the INTerpath-001 press release describing primary endpoint (RFS) and key secondary endpoint (DMFS) findings from the randomized phase 3 study of individualized neoantigen therapy plus pembrolizumab for resected stage IIB to IV melanoma. No data were shared, only descriptive findings of "statistically signficant" and "clinically meaningful&qu...

Ep 86: Tudriqev (RP1) FDA Approval 25.08.2026

In this episode, James and Sapna debate how to pronounce the newest FDA approved treatment for melanoma: T-U-D-R-I-Q-E-V They discuss the FDA Cell and Gene Therapy Advisory Committee's review of the single-arm IGNYTE data and key issues around if this represents a local or systemic therapy, the maths around calculating response rate, and importantly how to identify optimal tumor characteristic...

Ep 85: Surgical considerations for TIL 28.07.2026

In this episode, Sapna and James talk tv shows - The Gambler and His Cowboys, Brassic... They discuss the paper from NKI on surgical considerations for TIL harvest published in BJS in 2025. Topics of interest include optimal anatomic site(s), size (is bigger always better?), number of lesions and which of these components comprise a successful ex vivo expansion of TIL

Ep 84: Merlin CP-GEP and Castle i31-SLNB tests 24.07.2026

In this episode, the chin dimple is front and center. James explains the wizarding home of Tintagel in Cornwall to Sapna, situated on a lovely promontory. This episode explores the latest evidence on gene expression profile tests—Merlin 001 study of CP-GEP and Castle i31-SLNB —used to predict sentinel lymph node positivity in melanoma. James and Sapna discuss the study designs, clinical utility, a...

Ep 83: Guest Megan Othus and Time of Day Administration 24.06.2026

James and Sapna welcome Megan Othus, Professor of Biostatistics at the Fred Hutch Cancer Center and one of the key statisticians at SWOG. Megan talks about growing up in the PNW and going East to get back West. She helps us digest the time of day analyses and some of the missing analyses that should have been shown in the papers published to date. She teaches us about confounders, accounting for m...

Ep 82: Best of ASCO: 2026 13.06.2026

In this episode, James & Sapna tease the size of ASCO and ESMO and number of simultaneous publications. They review the most impactful melanoma and Merkel cell carcinoma presentations from ASCO 2026, focusing on practice-changing trials and innovative strategies that could shape future treatment landscapes. Studies discussed include: OptimUM-02 phase 2/3 trial for metastatic uveal melanoma ADA...

Live from ASCO 2026: a preview 01.06.2026

James & Sapna sent a brief message from ASCO 2026 about what they are looking forward to hearing at the meeting. OptimUM-02 ADAM KN-942 Neoadjuvant pilot studies ... and more

Ep 81: IGNYTE trial (RP1 + nivo) 13.02.2026

Summary The conversation covers the published data from the IGNYTE study - RP1 + nivolumab: response rate and safety profile, RNA-seq analysis, and toxicity. The key takeaways include insights into clinical trial interpretation and treatment efficacy (and incorrect graphs). Takeaways Clinical Trial Data Treatment Efficacy Chapters 00:00 Introduction to IGNYTE Study 14:04 Response Rate and Safety P...

Ep 80: 2025 Holiday Special 30.12.2025

Summary Happy Holidays and Festive Season Everyone! In this episode of Melanoma Matters, hosts Sapna Patel and James reflect on their "cultural" experiences over the past year, discussing movies, music, books, plays, and television shows. They share personal anecdotes about memorable trips, culinary highlights, gym feats, and their podcasting journey, while also looking ahead to their go...

Ep 79: coBRIM, COMBI-d 5-year follow-up 29.12.2025

Summary In this episode of Melanoma Matters, James awaits an invitation to a film premiere (The Penguin Lessons) and we all await a picture of him in his tuxedo! Sapna and James go on to discuss the 5-year outcomes of studies such as coBRIM, COMBI-d, and how those compare to 5-year benchmarks from the COLUMBUS study. They explore subgroups and characteristics of favorable (and durable) response, t...

Ep 78 TRAILER: MEK inhibitor trials 29.12.2025

Enjoy this short trailer on MEK inhibitor monotherapy trials in melanoma

Ep 78: MEK inhibitor trials (METRIC, NEMO, pimasertib) 29.12.2025

Summary So many shoutouts in this episode of Melanoma Matters! Sapna and James engage in a lively discussion about MEK inhibitors as monotherapy treatment. They explore the METRIC, NEMO, and pimasertib trials, and discuss side effects associated with this class of therapy. Sapna clears her own confusion regarding the PDUFA date for the NEMO study, and James objects to the way the NEMO abbreviation...

Ep 77: Guest Merrick Ross 29.12.2025

Summary In this episode of Melanoma Matters, hosts James Larkin and Sapna Patel engage with Merrick Ross, a seasoned surgical oncologist, discussing his background, the evolution of surgical practice with regards to melanoma treatment, and the importance of multidisciplinary collaboration. They explore innovations in neoadjuvant therapy, the critical role of pathology in treatment decisions, and t...

Ep 76: KEYNOTE 054 7-year follow-up 28.12.2025

Summary In this Episode, hosts James & Sapna go into the 7-year follow-up from the randomized phase 3 adjuvant trial of pembrolizumab versus placebo for stage III melanoma, KEYNOTE-054 There's a bit too much talk about weightlifting though...

Ep 75: Immune-mediated Myocarditis 28.12.2025

Summary In this (longest to-date) episode, James and Sapna delve into the not-so-rare occurence of immune-mediated myocarditis, particularly in the context of immune checkpoint inhibitors. The hosts discuss grading systems, management strategies, and the challenges of diagnosing and treating myocarditis. They emphasize the importance of close follow-up and the need for collaboration with cardiolog...

Ep 74: Best of ESMO 2025: Part 2 of 2 22.12.2025

Summary In this Part 2 Best of ESMO 2025 episode of Melanoma Matters, hosts James Larkin and Sapna Patel cover the IO Biotech phase 3 trial, Checkmate 238 final results, the Safe Stop trial, the ECOG-ACRIN STAMP trial for Merkel cell carcinoma, and a promising TCR therapy for uveal melanoma. Keywords melanoma, cancer research, immunotherapy, clinical trials, ESMO, IO Biotech, Checkmate 238, Safe S...

Ep 73: Best of ESMO 2025: Part 1 of 2 11.11.2025

We did it! We recorded a live teaser and a now a timely Best of ESMO 2025 episode... Part 1 of 2! In this episode, hear host James Larkin's favorite childhood vacations (dry skiing, upside down toothbrush hills and Mallorca... so privileged) James & Sapna focus on the 3 neoadjuvant melanoma presentations at ESMO 2025 and take a deep dive in to the results and questions raised for clinic on...

ESMO 2025 preview 22.10.2025

Enjoy this brief behind-the-scenes discussion from ESMO 2025 where we plan our upcoming Best of ESMO episode #ESMO25 #ESMO26 @melanomamatterspod

Ep 72 TRAILER: Quiz show - new drug approvals in 2024 09.10.2025

Enjoy this trailer of Episode 72 - James takes a test!

Ep 72: Quiz show - new drug approvals in 2024 (yes we're late...) 09.10.2025

For the record, we recorded this episode in February 2024 :) better late than never to get it published! In this episode, James has no idea what he's in for. Sapna quizzes James on new drug approvals in hematology & oncology in the year 2024 to see if he can guess the cancer type and mechanism of action.

Ep 71: Women in Melanoma manuscript - now with a FACT CHECK! 02.08.2025

Summary In this episode, hosts James Larkin & Sapna Patel discuss the Women in Melanoma Conference, highlighting its role in fostering networking and collaboration among female oncologists. They reflect on the evolution of the conference, its impact on participants, and the importance of addressing women's issues in oncology. The discussion also touches on the potential for expanding the i...

Listen to the Melanoma Matters podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.